Do or Die: HPV E5, E6 and E7 in Cell Death Evasion

被引:11
|
作者
Skelin, Josipa [1 ]
Sabol, Ivan [1 ]
Tomaic, Vjekoslav [1 ]
机构
[1] Rudjer Boskovic Inst, Div Mol Med, Bijenicka Cesta 54, Zagreb 10000, Croatia
来源
PATHOGENS | 2022年 / 11卷 / 09期
关键词
E5; E6; E7; HPV; cervical cancer; apoptosis; autophagy; anoikis; pyroptosis; HUMAN-PAPILLOMAVIRUS TYPE-16; PDZ BINDING MOTIF; SQUAMOUS INTRAEPITHELIAL LESIONS; RISK HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; MEDIATED APOPTOSIS; HUMAN KERATINOCYTES; GENE-EXPRESSION; LIFE-CYCLE; PROTECTS CELLS;
D O I
10.3390/pathogens11091027
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human papillomaviruses (HPVs) infect the dividing cells of human epithelia and hijack the cellular replication machinery to ensure their own propagation. In the effort to adapt the cell to suit their own reproductive needs, the virus changes a number of processes, amongst which is the ability of the cell to undergo programmed cell death. Viral infections, forced cell divisions and mutations, which accumulate as a result of uncontrolled proliferation, all trigger one of several cell death pathways. Here, we examine the mechanisms employed by HPVs to ensure the survival of infected cells manipulated into cell cycle progression and proliferation.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy
    Estevao, Diogo
    Costa, Natalia Rios
    Gil da Costa, Rui M.
    Medeiros, Rui
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2019, 1862 (02): : 153 - 162
  • [2] The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis
    Basukala, Om
    Banks, Lawrence
    VIRUSES-BASEL, 2021, 13 (10):
  • [3] Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells
    Boulenouar, Selma
    Weyn, Christine
    Van Noppen, Melody
    Ali, Mohamed Moussa
    Favre, Michel
    Delvenne, Philippe O.
    Bex, Francoise
    Noel, Agnes
    Englert, Yvon
    Fontaine, Veronique
    CARCINOGENESIS, 2010, 31 (03) : 473 - 480
  • [4] RNA (E6 and E7) Assays versus DNA (E6 and E7) Assays for Risk Evaluation for Women Infected with Human Papillomavirus
    Cattani, Paola
    Siddu, Alessia
    D'Onghia, Sara
    Marchetti, Simona
    Santangelo, Rosaria
    Vellone, Valerio G.
    Zannoni, Gian Franco
    Fadda, Giovanni
    JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (07) : 2136 - 2141
  • [5] Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites
    Tomaic, Vjekoslav
    CANCERS, 2016, 8 (10)
  • [6] HPV16/18 E5, a promising candidate for cervical cancer vaccines, affects SCPs, cell proliferation and cell cycle, and forms a potential network with E6 and E7
    Liao, Shujie
    Deng, Dongrui
    Hu, Xiaoji
    Wang, Wei
    Li, Li
    Li, Wei
    Zhou, Jianfeng
    Xu, Gang
    Meng, Li
    Wang, Shixuan
    Ma, Ding
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 31 (01) : 120 - 128
  • [7] THE CARCINOGENIC POTENTIAL OF E6 & E7 GENES OF HIGH-RISK HPV COMPARED WITH E6, E7 GENES OF LOW-RISK HPV IN HUMAN CERVICAL CANCER: A REVIEW
    Gill, Sher Singh
    Jana, A. M.
    Shrivastav, Archana
    Sharma, Sachin
    Sharma, Arvind
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2014, 5 (03): : 703 - 712
  • [8] Uniplex E6/E7 PCR method detecting E6 or E7 genes in 39 human papillomavirus types
    Okodo, Mitsuaki
    Okayama, Kaori
    Teruya, Koji
    Sasagawa, Toshiyuki
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (05) : 981 - 988
  • [9] Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer
    Stiasny, Annika
    Kuhn, Christina
    Mayr, Doris
    Alexiou, Christoph
    Janko, Christina
    Wiest, Irmi
    Jeschke, Udo
    Kost, Bernd
    ANTICANCER RESEARCH, 2016, 36 (06) : 3195 - 3198
  • [10] Anticancer Drugs Aimed at E6 and E7 Activity in HPV-Positive Cervical Cancer
    Tan, S.
    de Vries, E. G. E.
    van der Zee, A. G. J.
    de Jong, S.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (02) : 170 - 184